Lorena Aguado

Ms. Lorena Aguado


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PBPedro Blanco-Hernán
Pedro Blanco-Hernán
LALorena Aguado
Lorena Aguado
MVMARIA JOSE ASENSIO VEGAS
MARIA JOSE ASENSIO VEGAS
ASAna Gómez Soria
Ana Gómez Soria
PVPedro de la Villa
Pedro de la Villa
AMAlicia Mansilla
Alicia Mansilla
Retinal dysfunction is emerging as a potential early marker of neurodegenerative diseases. Within the retina, the dopaminergic circuit, comprising dopaminergic amacrine cells, dopamine synthesis and turnover, and dopamine receptor signalling, is essential for visual processing, particularly colour contrast perception. Disruption of this circuit may underline early retinal alterations observed in Huntington’s disease (HD) and Alzheimer’s disease (AD). In this study, we systematically analysed retinal dopaminergic dysfunction in murine models of HD (genetic origin) and AD (sporadic), across different disease stages. We assessed dopamine levels, turnover, tyrosine hydroxylase expression, D1 and D2 receptor gene expression, and neurotransmitter balance. HD mice showed early and marked alterations: reduced dopamine content, decreased tyrosine hydroxylase, increased turnover, and downregulation of D1 receptor expression—all preceding motor symptoms and detectable brain pathology. In contrast, AD mice showed only mild changes at later stages; however, clinical evidence suggests that similar dysfunction may occur earlier in human AD. These findings position retinal dopaminergic disruption as a potential early biomarker in HD and possibly in AD. While the current study relies on invasive techniques in animal models, it lays the groundwork for non-invasive retinal assessments, such as electroretinography or optical coherence tomography, as promising tools for early diagnosis and disease monitoring in neurodegeneration.

16 November 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
EGEduardo González-García
Eduardo González-García
CMCelia Miró-Rodríguez
Celia Miró-Rodríguez
EUEugenia Ulzurrun
Eugenia Ulzurrun
OTOscar Toledano
Oscar Toledano
SPSara Pérez-Suarez
Sara Pérez-Suarez
NCNuria E. Campillo
Nuria E. Campillo
Drug repurposing is an efficient strategy to accelerate the identification of thera- peutic compounds by finding new uses for existing drugs. Here, we leveraged artifi- cial intelligence (AI) to optimize this process and discover protein-protein interaction (PPI) modulators targeting the Neuronal Calcium Sensor 1. AI models were trained on large datasets of known PPIs, protein structures, and small molecular graphs to predict binding score. Using virtual screening of an FDA-approved drug library, the models generated a prioritized list of candidates. The most promising compounds were selected for experimental validation. This integrated approach efficiently reduced ex- perimental workload, time, and cost, leading to the identification of dipyridamole as a selective modulator of the interaction between NCS-1 and the dopamine D2 receptor. The crystal structure of NCS-1 in complex with dipyridamole elucidates its mechanism of modulation. Our findings highlight the potential of AI to streamline and accelerate the discovery of novel therapeutic PPI modulators